ALPM.Y 주식 개요 는 일본 및 국제적으로 의약품을 제조, 판매, 수출입하는 회사입니다. 자세한 내용
{"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
생각, 링크 및 회사 내러티브를 캡처하세요.
가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Astellas Pharma 과거 주가 현재 주가 JP¥9.53 52주 최고치 JP¥13.14 52주 최저치 JP¥9.05 베타 0.23 1개월 변경 0.63% 3개월 변경 사항 -11.27% 1년 변경 사항 -12.49% 3년 변화 -44.83% 5년 변화 -44.09% IPO 이후 변화 29.16%
최근 뉴스 및 업데이트 Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer Feb 11
Astellas Pharma Inc. Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan Feb 05
Astellas Pharma Inc. Announces Management Changes, Effective April 1, 2025 Feb 04 Astellas Receives Health Canada Approval for Vyloy® (Zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
Astellas Pharma Inc. Announces China's National Medical Products Administration (Nmpa) Approves Padcev™ in Combination with Keytruda® (Pembrolizumab) for the Treatment of Advanced Bladder Cancer Jan 08
China's National Medical Products Administration Approves Vyloy (Zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Jan 06 더 많은 업데이트 보기 Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer Feb 11
Astellas Pharma Inc. Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan Feb 05
Astellas Pharma Inc. Announces Management Changes, Effective April 1, 2025 Feb 04 Astellas Receives Health Canada Approval for Vyloy® (Zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
Astellas Pharma Inc. Announces China's National Medical Products Administration (Nmpa) Approves Padcev™ in Combination with Keytruda® (Pembrolizumab) for the Treatment of Advanced Bladder Cancer Jan 08
China's National Medical Products Administration Approves Vyloy (Zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Jan 06
Astellas Pharma Inc. to Report Q3, 2025 Results on Feb 04, 2025 Jan 03
Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer Oct 19 Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024 Oct 05
Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024 Oct 04
Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer Sep 24
Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society Sep 04
European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer Aug 28
Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy Aug 27
Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer Aug 20 Astellas Pharma Inc. Receives Positive Chmp Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer
Astellas Pharma Inc. to Report Q1, 2025 Results on Aug 01, 2024 Jun 29 U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date May 31
Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting Apr 25 Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024
Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024 Apr 03
U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy Apr 02
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer Mar 28
Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer Mar 27
Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting Mar 22
Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan Mar 05
Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDA Feb 16
Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer Jan 31 European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer Jan 27
Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.S Jan 09
Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024 Dec 28
Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children Dec 18 Pfizer Inc. and Astellas Pharma Inc. Announce U.S. Food and Drug Administration Approved PADCEV (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA (pembrolizumab, a PD-1 inhibitor) for the Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC) Dec 16
Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause Dec 11
Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis Dec 09
Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer Dec 02
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy Nov 30 Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus Chemotherapy Oct 24
Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023 Oct 16
Astellas Receives Positive Chmp Opinion for Veoza (Fezolinetant) Oct 14
Astellas Pharma Inc. to Report Q2, 2024 Results on Nov 01, 2023 Sep 28
Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial Sep 23 Astellas Pharma Inc. Announces China's National Medical Products Administration Accepts New Drug Application for Xtandi®? (Enzalutamide) in Metastatic Hormone-S Sensitive Prostate Cancer
Astellas Pharma Inc. Announces Positive 24-Month Topline Results from the Phase 3 GATHER2 Clinical Trial Evaluating the Efficacy and Safety of IZERVAY Sep 19
European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence Sep 13
Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503). Aug 30
Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503). Aug 29 FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence Aug 24
Astellas Pharma Inc. Announces European Medicines Agency Accepts for Regulatory Review the Marketing Authorization Application for Avacincaptad Pegol Aug 18
U.S. FDA Accepts Astellas Pharma US, Inc.'s sNDA for CRESEMBA® (isavuconazonium sulfate) in Children Aug 11
Astellas Pharma Inc. Announces the U.S. Food and Drug Administration Approves Izervay (Avacincaptad Pegol Intravitreal Solution) for the Treatment of Geographic At the 12-Month Primary Endpoint Across Two Phase 3 Clinical Trials Aug 09 Astellas Pharma Inc. Revises Consolidated Earnings Guidance on Full Basis for the Full-Year 2023 Aug 03
China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab Aug 01
European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab Jul 14
Astellas Pharma Inc. to Report Q1, 2024 Results on Aug 01, 2023 Jul 12
Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application Jul 06
Astellas Pharma Inc. Announces Positive Topline Results from the Phase 3b DayLIGHT Clinical Trial for Fezolinetant Jun 28
Astellas Pharma Inc. Confirms Unfavorable District Court Decision in Myrbetriq U.S. Patent Trial Jun 12
Astellas Pharma Inc. Announces Submission of New Drug Application to Japan's Ministry of Health, Labour and Welfare for Zolbetuximab Jun 09
Astellas' Veozah Tm (Fezolinetant) Approved by U.S. Fda for Treatment of Vasomotor Symptoms Due to Menopause May 17 Astellas Pharma Inc. Provides Update on Fezolinetant New Drug Application in U.S Feb 20
Astellas Pharma Inc. Reaffirms Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 Astellas Pharma Inc. Announces CEO Changes, Effective April 1, 2023
Sandoz AG agreed to acquire Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503). Jan 25
Sandoz AG agreed to acquire Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503). Jan 24
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease Jan 21
Astellas Pharma Inc. Presents Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium Jan 20
Astellas Pharma Inc. Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions Jan 19
Astellas Pharma Inc. to Report Q3, 2023 Results on Feb 06, 2023 Dec 29
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer Dec 21 주주 수익률 ALPM.Y US Pharmaceuticals US 마켓 7D 4.2% 1.2% 0.2% 1Y -12.5% 1.4% 23.1%
전체 주주 수익률 보기
수익률 대 산업: ALPM.Y 지난 1년 동안 1.4 %를 반환한 US Pharmaceuticals 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: ALPM.Y 지난 1년 동안 23.1 %를 반환한 US 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is ALPM.Y's price volatile compared to industry and market? ALPM.Y volatility ALPM.Y Average Weekly Movement 2.9% Pharmaceuticals Industry Average Movement 10.1% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
안정적인 주가: ALPM.Y 지난 3개월 동안 US 시장에 비해 상당한 가격 변동성이 발생하지 않았습니다.
시간에 따른 변동성: ALPM.Y 의 주간 변동성 ( 3% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 는 일본 및 해외에서 의약품을 제조, 판매, 수출입하는 기업입니다. 이 회사는 전립선암 치료제인 엑스탄디, FLT3 변이가 있는 재발성 또는 불응성 급성 골수성 백혈병 환자 치료제인 조스파타, 전이성 요로상피암 환자 치료제인 패드세브 등을 공급하고 있습니다. 또한 만성 신장 질환과 관련된 빈혈 치료제인 에브렌조, 과민성 방광 치료제인 베타니스/미라베트릭/베트미가, 면역 억제제인 프로그라프와 애드바그라프/그레이스펙터/아스타그라프 XL을 제공하고 있습니다.
자세히 보기 Astellas Pharma Inc. 기본 사항 요약 Astellas Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요? ALPM.Y 기본 통계 시가총액 US$17.05b 수익(TTM ) -US$376.42m 수익(TTM ) US$12.24b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) ALPM.Y 손익 계산서(TTM ) 수익 JP¥1.87t 수익 비용 JP¥345.58b 총 이익 JP¥1.52t 기타 비용 JP¥1.58t 수익 -JP¥57.43b
주당 순이익(EPS) -32.08 총 마진 81.50% 순이익 마진 -3.07% 부채/자본 비율 61.3%
ALPM.Y 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/11 08:13 장 마감 주가 2025/02/11 00:00 수익 2024/12/31 연간 수익 2024/03/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기 .
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.
애널리스트 출처 Astellas Pharma Inc. 30 애널리스트 중 15 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Atsushi Seki Barclays Koichi Mamegano BofA Global Research Hazim Bahari CFRA Equity Research
27 더 많은 분석가 보기 
